# Beacon gene therapy meets U.S. endpoint in pivotal vision trial

_Published Monday, September 21, 2026 at 12:19 PM EDT · Science · Latest · Tier 1 — Major_

![Beacon gene therapy meets U.S. endpoint in pivotal vision trial — Primary](https://european-biotechnology.com/wp-content/uploads/2026/09/levi-meir-clancy-KvsBhEJHhUI-unsplash-scaled.jpg)

Beacon Therapeutics' laru-zova gene therapy met the U.S. primary endpoint in a Phase 2/3 trial of 85 boys and men with RPGR-associated X-linked retinitis pigmentosa. After 12 months, 31.0% of high-dose patients and 24.1% of low-dose patients gained at least 15 letters in dim-light visual acuity, compared with 0% of untreated controls.

The one-time treatment delivers a functioning RPGR copy beneath the retina after vitrectomy. Europe's separately designated retinal-sensitivity measure produced mixed statistical results across doses, and two serious ocular events in the low-dose group were attributed to surgery.

## Sources

- [European Biotechnology Magazine](https://european-biotechnology.com/latest-news/beacons-xlrp-gene-therapy-meets-pivotal-u-s-endpoint/)

---
Canonical: https://techandbusiness.org/newswire/o0FVI1mDRCKgJH-At3ZJkk
Published: 2026-09-21T16:19:44.590Z
Story chronology: 2026-09-21T15:33:27.000Z
Retrieved: 2026-09-21T18:19:18.321Z
Publisher: Tech & Business (techandbusiness.org)